Bonaduce D, Muto P, Morgano G, Canonico V, Breglio R, Salvatore M, Condorelli M
Clin Cardiol. 1986 Jun;9(6):285-8. doi: 10.1002/clc.4960090610.
The effect of a calcium antagonist drug, nifedipine, on dipyridamole thallium-201 images was assessed in 10 angina patients with positive dipyridamole test. Two dipyridamole thallium-201 tests were performed, the first in basal conditions, the second after administration of 20 mg nifedipine. After dipyridamole, heart rate and double product increased respectively from 68.0 +/- 8.2 to 94.7 +/- 11.5 beats/min (p less than 0.01) and from 9459.5 +/- 1800.2 to 12,770.0 +/- 1864.7 mmHg X beats/min (p less than 0.01). Dipyridamole when infused after nifedipine induced an increase in heart rate from 74.2 +/- 7.16 to 88.8 +/- 5.6 beats/min (p less than 0.01) and in double product from 9650.5 +/- 1348.0 to 11,399.0 +/- 1146 mmHg X beats/min (p less than 0.05). Systolic and diastolic blood pressures were unmodified during the two studies. Segment scores were comparable before and after nifedipine. Thus, nifedipine does not worsen thallium-201 myocardial images obtained during dipyridamole infusion, therefore, this test could provide an alternative to exercise thallium-201 in patients receiving calcium antagonist drugs.
在10例双嘧达莫试验阳性的心绞痛患者中评估了钙拮抗剂药物硝苯地平对双嘧达莫铊-201心肌显像的影响。进行了两次双嘧达莫铊-201试验,第一次在基础状态下进行,第二次在给予20mg硝苯地平后进行。双嘧达莫给药后,心率和心率与收缩压乘积分别从68.0±8.2次/分钟增加至94.7±11.5次/分钟(p<0.01),以及从9459.5±1800.2mmHg·次/分钟增加至12770.0±1864.7mmHg·次/分钟(p<0.01)。硝苯地平给药后输注双嘧达莫使心率从74.2±7.16次/分钟增加至88.8±5.6次/分钟(p<0.01),心率与收缩压乘积从9650.5±1348.0mmHg·次/分钟增加至11399.0±1146mmHg·次/分钟(p<0.05)。在两项研究期间,收缩压和舒张压均未改变。硝苯地平前后的节段评分具有可比性。因此,硝苯地平不会使双嘧达莫输注期间获得的铊-201心肌显像恶化,所以,对于接受钙拮抗剂药物治疗的患者,该试验可为运动铊-201试验提供一种替代方法。